Empagliflozin + Linagliptin

Phase 3

Eli Lilly and Company (LLY)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

13 competitors in Diabetes Mellitus, Type 2

NVOInsulin Icodec

Phase 3

NVOInsulin Glargine 100U/mL

Phase 3

JNJJNJ-41443532

Phase 2

MNKDTechnosphere/Insulin

Phase 2

AZNB - Exenatide 10 mcg twice daily

Phase 2

View Full Landscape

Drug Information

Target Indication

Diabetes Mellitus, Type 2

Clinical Trial

NCT01734785

Last updated: 10/23/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

LLY

Eli Lilly and Company

Pharmaceutical Preparations•North America•NYSE

Related Pipeline

BI10773Phase 3

Diabetes Mellitus, Type 2

BI 10773 open labelPhase 3

Diabetes Mellitus, Type 2

Insulin lispro 6 day reservoir in-usePhase 3

Diabetes Mellitus, Type 1

Intracoronary infusion of enriched bone marrow-derived progenitor cellsPhase 3

Myocardial Infarction

SulfonylureasPhase 3

Type 2 Diabetes Mellitus

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts